Publication Name	World Journal of Gastroenterology
Manuscript ID	9538
Country	Israel

Received	2014-02-16 20:37
Peer-Review Started	2014-02-16 21:20
First Decision by Editorial Office Director
Return for Revision	2014-04-21 19:47
Revised	2014-05-01 20:57
Publication Fee Transferred
Second Decision by Editor	2014-06-13 11:53
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2014-06-13 12:38
Articles in Press	2014-06-13 13:04
Edit the Manuscript by Language Editor	2014-08-07 17:17
Typeset the Manuscript	2014-10-20 16:41
Publish the Manuscript Online	2014-10-29 19:34

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Halofuginone for fibrosis, regeneration and cancer in the gastrointestinal tract
Manuscript Source	Unsolicited Manuscript
All Author List	Mark Pines
Funding Agency and Grant Number
Corresponding Author	Mark Pines, PhD, Institute of Animal Sciences, the Volcani Center, PO Box 6, Bet Dagan 50250, Israel. mark.pines@mail.huji.ac.il
Key Words	Stellate cell; Myofibroblast; Transforming growth factor a; Extracellular matrix; Cancer
Core Tip	Fibrosis is a pathological process associated with excessive deposition of extracellular matrix that leads to destruction of organ architecture and function. Fibrosis contributes enormously to deaths worldwide, thus therapies are of a great need. The concept of common fibrosis pathways that could be therapeutic targets in all organs is an attractive one. Halofuginone is a novel anti-fibrotic therapy that inhibits tissue fibrosis, regeneration, and development of tumors in tissues along the gastrointestinal tract. At present halofuginone is being evaluated in a clinical trial for another fibrotic indication, and any clinical success there would allow its use for all other fibrotic indications.
Publish Date	2014-10-29 19:34
Citation	Pines M. Halofuginone for fibrosis, regeneration and cancer in the gastrointestinal tract. World J Gastroenterol 2014; 20(40): 14778-14786
URL	http://www.wjgnet.com/1007-9327/full/v20/i40/14778.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i40.14778

Full Article (PDF)	WJG-20-14778.pdf
Full Article (Word)	WJG-20-14778.doc
Manuscript File	9538-Review.docx
Answering Reviewers	9538-Answering reviewers.pdf
Copyright License Agreement	9538-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	9538-Language certificate.pdf
Peer-review Report	9538-Peer review.pdf
Scientific Misconduct Check	9538-CorssCheck.jpg
Scientific Editor Work List	9538-Scientific editor work list.pdf